Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1426]

ASCENT: A phase II trial of induction, consolidation and maintenance in...

Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA

ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk smouldering MM ( Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA )

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Prof Monica Bocchia - University of Siena, Siena, Italy

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment ( Prof Monica Bocchia - University of Siena, Siena, Italy )

Treating acute leukaemias of ambiguous lineage

Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research...

Treating acute leukaemias of ambiguous lineage ( Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Hospital, USA )

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D)...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin...

Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia

$Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data ( Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia )$

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5...

Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

FORTE trial: Impact of minimal residual disease on multiple myeloma patients ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL...

Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol ( Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands )

PARP inhibitors in prostate cancer: A promise delivered

Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA

PARP inhibitors in prostate cancer: A promise delivered ( Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA )

Clinical genomic testing in prostate cancer

Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA

Clinical genomic testing in prostate cancer ( Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA )

PARP inhibitors for prostate cancer - Nurse's view

Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA

PARP inhibitors for prostate cancer - Nurse's view ( Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA )

Using circulating tumour DNA dynamics to predict outcomes in advanced cancers

Dr Mohamed Gouda - The University of Texas MD Anderson Cancer Center, Houston...

Using circulating tumour DNA dynamics to predict outcomes in advanced cancers ( Dr Mohamed Gouda - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer